このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進展期小細胞肺がん(IDeate-Lung03)患者における第一選択の導入または維持として、カルボプラチンの有無にかかわらずアテゾリズマブとI-DXdを併用する研究

2026年9月28日 更新者:Daiichi Sankyo

第一選択の導入または維持として、カルボプラチンの有無にかかわらずアテゾリズマブと併用した、B7-H3 抗体薬物複合体 (ADC) であるイフィナタマブ デルクステカン (I-DXd) の第 1b/2 相多施設共同非盲検試験進展期小細胞肺がん(ES-SCLC)の被験者(IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

調査の概要

詳細な説明

This study consists of two parts and two cohorts: Part A (Phase 1b; Safety Run-in) and Part B (Phase 2; Dose Optimization), Cohort 1 (I-DXd in maintenance) and Cohort 2 (I-DXd in induction + maintenance).

The primary objective of this study is to evaluate the safety and tolerability of I-DXd in combination with atezolizumab with or without carboplatin by assessing treatment-emergent adverse events (TEAEs) and other safety parameters which will inform optimal dose selection of I-DXd in the combination regimens (Dose Optimization Part B) of this study.

研究の種類

介入

入学 (推定)

123

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • 募集
        • University of Alabama -Birmingham
        • コンタクト:
          • Principal Investigator
    • Arizona
      • Phoenix、Arizona、アメリカ、85054
        • 募集
        • Mayo Clinic Arizona
        • コンタクト:
          • Principal Investigator
    • California
      • Los Angeles、California、アメリカ、90095
        • まだ募集していません
        • David Geffen School of Medicine
        • コンタクト:
          • Principal Investigator
      • Newport Beach、California、アメリカ、92663
        • 募集
        • Hoag Memorial Hospital Presbyterian
        • コンタクト:
          • Principal Investigator
    • Florida
      • Jacksonville、Florida、アメリカ、32224
        • 募集
        • Mayo Clinic-Jacksonville
        • コンタクト:
          • Principal Investigator
      • Orlando、Florida、アメリカ、32804
        • 募集
        • Advent Health Orlando
        • コンタクト:
          • Principal Investigator
      • Tampa、Florida、アメリカ、33612
        • 募集
        • Moffitt Cancer Center
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • 募集
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
        • コンタクト:
          • Principal Investigator
    • Michigan
      • Detroit、Michigan、アメリカ、48202
        • 積極的、募集していない
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55455
        • 募集
        • Regents of the University of Minnesota
        • コンタクト:
          • Principal Investigator
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic
        • コンタクト:
          • Principal Investigator
    • New Hampshire
      • Lebanon、New Hampshire、アメリカ、03766
        • 募集
        • Dartmouth-Hitchcock Medical Center
        • コンタクト:
          • Principal Investigator
    • New Jersey
      • East Brunswick、New Jersey、アメリカ、08816
        • 募集
        • Astera Cancer Care
      • Hackensack、New Jersey、アメリカ、07601
        • 募集
        • John Theurer Cancer Center At Hackensack Umc
        • コンタクト:
          • Principal Investigator
    • New York
      • Mineola、New York、アメリカ、11501
        • 募集
        • NYU Langone Hospital - Long Island
        • コンタクト:
          • Principal Investigator
      • Mineola、New York、アメリカ、11501
        • 募集
        • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone
        • コンタクト:
          • Principal Investigator
      • New York、New York、アメリカ、10021
        • 募集
        • Memorial Sloan Kettering Cancer Center
        • コンタクト:
          • Principal Investigator
      • New York、New York、アメリカ、10461
        • 募集
        • Montefiore Medical Center
      • New York、New York、アメリカ、10032
        • 募集
        • Columbia University Hervert Irving Comprehensive Cancer Center
        • コンタクト:
          • Principal Investigator
    • Pennsylvania
      • Lancaster、Pennsylvania、アメリカ、17601
        • 募集
        • Lancaster General Hospital - Ann B Barshinger Cancer Institute
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • University of Pennsylvania, Abramson Cancer Center
      • Philadelphia、Pennsylvania、アメリカ、19107
        • 募集
        • Thomas Jefferson University Hospital - Central
        • コンタクト:
          • Principal Investigator
    • Tennessee
      • Nashville、Tennessee、アメリカ、37203
        • 募集
        • Scri Oncology Partners
        • コンタクト:
          • Principal Investigator
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • 募集
        • Next Virginia
        • コンタクト:
          • Principal Investigator
    • Washington
      • Vancouver、Washington、アメリカ、98684
        • 募集
        • Northwest Cancer Specialists, P.C.-Vancouver
        • コンタクト:
          • Principal Investigator
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • 募集
        • Medical College of Wisconsin
        • コンタクト:
          • Principal Investigator
      • Barcelona、スペイン、08036
        • 募集
        • Hospital Clinic de Barcelona
        • コンタクト:
          • Principal Investigator
      • Barcelona、スペイン、8035
        • 募集
        • Hospital Universitari Vall D'Hebron
        • コンタクト:
          • Principal Investigator
      • Girona、スペイン、17007
        • 募集
        • Ico Girona - Hospital Universitari de Girona Dr Josep Trueta
        • コンタクト:
          • Principal Investigator
      • L'Hospitalet de Llobregat、スペイン、08908
        • 募集
        • ICO l'Hospitalet - Hospital Duran i Reynals
        • コンタクト:
          • Principal Investigator
      • Madrid、スペイン、28041
        • 募集
        • Hospital Universitario 12 de Octubre
        • コンタクト:
          • Principal Investigator
      • Madrid、スペイン、28007
        • 募集
        • Hospital General Universitario Gregorio Marañon
        • コンタクト:
          • Principal Investigator
      • Madrid、スペイン、28034
        • 募集
        • Hospital Universitario Ramon Y Cajal
        • コンタクト:
          • Principal Investigator
      • Madrid、スペイン、28223
        • 募集
        • Next Madrid
        • コンタクト:
          • Principal Investigator
      • Málaga、スペイン、29010
        • 募集
        • Hospital Regional Universitario de Malaga
        • コンタクト:
          • Principal Investigator
      • Seville、スペイン、41009
        • 募集
        • Hospital Universitario Virgen Macarena
        • コンタクト:
          • Principal Investigator
      • Seville、スペイン、41013
        • 募集
        • Hospital Universitario Virgen Del Rocio
        • コンタクト:
          • Principal Investigator
      • Vigo、スペイン、36312
        • 募集
        • Hospital Alvaro Cunqueiro
        • コンタクト:
          • Principal Investigator
      • Lille、フランス、59037
        • 募集
        • Hopital Albert Calmette - Chu Lille
        • コンタクト:
          • Principal Investigator
      • Lyon、フランス、69008
        • 募集
        • Centre Léon Bérard
        • コンタクト:
          • Principal Investigator
      • Marseille、フランス、13005
        • 募集
        • Hôpital de la Timone
        • コンタクト:
          • Principal Investigator
      • Paris、フランス、75005
        • 募集
        • Institut Curie - Site de Paris
        • コンタクト:
          • Principal Investigator
      • Paris、フランス、75020
        • 募集
        • Hopital Tenon
        • コンタクト:
          • Principal Investigator
      • Rennes、フランス、35000
        • 募集
        • Chu Rennes - Hopital Pontchaillou
        • コンタクト:
          • Principal Investigator
      • Saint-Herblain、フランス、44805
        • 募集
        • CHU Nantes - Hôpital Guillaume et René Laënnec
        • コンタクト:
          • Principal Investigator
      • Suresnes、フランス、92151
        • 募集
        • Hôpital Foch
        • コンタクト:
          • Principal Investigator
      • Villejuif、フランス、94805
        • まだ募集していません
        • Institut Gustave Roussy
        • コンタクト:
          • Principal Investigator
      • Himeji-shi、日本、670-8520
        • 募集
        • NHO Himeji Medical Center
      • Hirakata-shi、日本、573-1191
        • 募集
        • Kansai Medical University Hospital
        • コンタクト:
          • Principal Investigator
      • Kashiwa、日本、277-8577
        • 募集
        • National Cancer Center Hospital East
        • コンタクト:
          • Principal Investigator
      • Kumamoto、日本、861-4193
        • 募集
        • Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
        • コンタクト:
          • Principal Investigator
      • Kōtoku、日本、135-8550
        • 募集
        • The Cancer Institute Hospital of Jfcr
        • コンタクト:
          • Principal Investigator
      • Nagaizumi-cho、日本、411-8777
        • 募集
        • Shizuoka Cancer Center
        • コンタクト:
          • Principal Investigator
      • Niigata、日本、951-8566
        • 募集
        • Niigata Cancer Center Hospital
        • コンタクト:
          • Principal Investigator
      • Okayama、日本、700-8558
        • 募集
        • Okayama University Hospital
        • コンタクト:
          • Principal Investigator
      • Tokushima、日本、770-8503
        • 募集
        • Tokushima University Hospital
      • Toyoake-shi、日本、470-1192
        • 募集
        • Fujita Health University Hospital
      • Ōsaka-sayama、日本、589-8511
        • 募集
        • Kindai University Hospital
        • コンタクト:
          • Principal Investigator

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

A full list of inclusion/exclusion criteria are available in the protocol.

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  1. Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.

  2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.

  3. Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line (IL) therapy.

  4. For Cohort 1, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per RECIST v1.1 assessed by the investigator.

    For Cohort 2, participant has received no prior treatment for ES-SCLC.

  5. For Cohort 2, participant has at least one measurable lesion according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator.

  6. For Cohort 2, participant must have at least one lesion, amenable to core biopsy, and must consent to provide a pretreatment biopsy tissue sample and on-treatment biopsy.

  7. Has ECOG PS of ≤1 (assessed within 7 days before enrollment/randomization).

  8. Has adequate organ and bone marrow function within 7 days before the start of study treatment as specified in the study protocol.

  9. A female subject of childbearing potential (POCBP) is eligible to participate if the following conditions are met:

    1. Subject is not pregnant as confirmed by highly sensitive pregnancy test during Screening (within 3 days prior to enrollment/randomization)
    2. Subject does not breastfeed during the treatment period and for at least 8/5/6 months after last dose of I-DXd/atezolizumab/carboplatin, respectively.
    3. Subject agrees to adhere to a contraceptive method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the treatment period and for at least the time needed to eliminate each study drug after the last dose. The length of time required to continue contraception and avoid donating/freezing eggs after last dose for I-DXd/atezolizumab/carboplatin is 8/5/6 months, respectively. Preservation of eggs may be considered prior to first dose of study drug.
  10. A male subject capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each study drug. The length of time required to continue contraception and avoid donating sperm after last dose for I-DXd/atezolizumab/carboplatin is 6/5/6 months, respectively.

    1. Avoid donating sperm.
    2. Adhere to either of the contraception methods: true abstinence from penile-vaginal intercourse or uses a penile/external condom when having penile-vaginal intercourse with a non-subject of childbearing potential plus partner use of an additional contraceptive method.
  11. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received prior treatment with CD137 agonists or ICIs, including anti-cytotoxic T-cell lymphocyte-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, except for atezolizumab for Cohort 1.
  4. Has inadequate washout period before enrollment/randomization as specified in the study protocol.
  5. Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
  6. Has clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
  7. Has clinically significant corneal disease.
  8. Has uncontrolled or significant cardiovascular disease,.
  9. Has history of (non-infectious) ILD/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease, topical steroids (for mild skin conditions), or intra-articular steroid injections.
  12. Has history of malignancy other than SCLC within the 5 years prior to randomization/enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
  13. Has history of allogeneic bone marrow, stem cell, or solid organ transplant.
  14. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE V5.0, Grade ≤1 or baseline.
  15. Has history of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
  16. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  17. Has active or uncontrolled human immunodeficiency virus (HIV) infection.
  18. Has active or uncontrolled hepatitis B or C virus (HBV or HCV) infection.
  19. Has history of autoimmune disease.
  20. Has any evidence of severe or uncontrolled systemic diseases.
  21. Has received a live vaccine within 30 days prior to the first dose of study drug.
  22. Is a female who is pregnant or breastfeeding or planning to become pregnant.
  23. Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
  24. Has psychological, social, familial, or logistical factors that would prevent regular follow-up

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure.

Intravenous administration

他の名前:
  • I-DXd

Intravenous administration

実験的:Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

他の名前:
  • I-DXd

Intravenous administration

Intravenous administration

実験的:Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

他の名前:
  • I-DXd

Intravenous administration

Intravenous administration

実験的:Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W

Intravenous administration

他の名前:
  • I-DXd

Intravenous administration

実験的:Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

他の名前:
  • I-DXd

Intravenous administration

実験的:Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

他の名前:
  • I-DXd

Intravenous administration

Intravenous administration

実験的:Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×minIV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

他の名前:
  • I-DXd

Intravenous administration

Intravenous administration

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
カルボプラチンの有無にかかわらずアテゾリズマブと I-DXd を併用した後に用量制限毒性を報告した参加者の数 (パート A)
時間枠:サイクル 1 1 日目からサイクル 1 21 日目まで (各サイクルは 21 日)
サイクル 1 1 日目からサイクル 1 21 日目まで (各サイクルは 21 日)
カルボプラチンの有無にかかわらずアテゾリズマブと併用した I-DXd 後に治療中に発現した有害事象が発生した参加者の総数 (パート A および B)
時間枠:ベースラインは最大 37 か月
ベースラインは最大 37 か月

二次結果の測定

結果測定
メジャーの説明
時間枠
Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
時間枠:From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months

Progression-free survival is defined as the time from the enrollment/randomization date to the earlier of the dates of the first documentation of disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause.

From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months
Objective Response Rate Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
時間枠:Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Objective response rate (ORR) is defined as proportion of subjects who achieved a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BICR and investigator according to RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Duration of Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
時間枠:From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months

Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed complete response [CR] or confirmed partial response [PR]) to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. The DoR will be calculated for responding participants (confirmed PR or confirmed CR) only.

From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months
Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
時間枠:Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD by BICR and investigator assessment per RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Clinical Benefit Rate as Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
時間枠:Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Clinical benefit rate (CBR) is defined as the proportion of participants who achieved a best overall response of confirmed CR, confirmed PR, or SD lasting for at least 180 days.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Time to Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
時間枠:From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months

Time to response (TTR) is defined as the time from the date of enrollment/randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding subjects.

From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months
Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
時間枠:Baseline up to approximately 37 months

The best percentage change in SoD is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

Baseline up to approximately 37 months
Overall Survival Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
時間枠:From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months

Time from the date of enrollment/randomization to the date of death due to any cause.

From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months
Pharmacokinetic Parameter Maximum Serum Concentration of I-DXd
時間枠:Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Maximum serum concentration (Cmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Time to Maximum Serum Concentration of I-DXd
時間枠:Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Time to maximum serum concentration (Tmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Area Under the Concentration Curve of I-DXd
時間枠:Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Area under the concentration-time curve up to the last quantifiable time (AUClast) and Area under the concentration-time curve during dosing interval (AUCtau) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody
時間枠:Baseline up to approximately 37 months

The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or postbaseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will be reported.

Baseline up to approximately 37 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Global Clinical Leader、Daiichi Sankyo

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年7月22日

一次修了 (推定)

2027年7月20日

研究の完了 (推定)

2028年2月20日

試験登録日

最初に提出

2024年1月2日

QC基準を満たした最初の提出物

2024年4月8日

最初の投稿 (実際)

2024年4月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • DS7300-189
  • 2023-509629-36 (その他の識別子:EU CT)
  • 2031240089 (その他の識別子:JRCT)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD 共有時間枠

Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD 共有アクセス基準

Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する